Cargando…
Dupilumab: a novel treatment for asthma
Simultaneously with the steady progress towards a better knowledge of the pathobiology of asthma, the potential usefulness of anticytokine therapies is emerging as one of the key concepts in the newly developing treatments of this widespread airway disease. In particular, given the key role played b...
Autores principales: | Vatrella, Alessandro, Fabozzi, Immacolata, Calabrese, Cecilia, Maselli, Rosario, Pelaia, Girolamo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159398/ https://www.ncbi.nlm.nih.gov/pubmed/25214796 http://dx.doi.org/10.2147/JAA.S52387 |
Ejemplares similares
-
Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021) -
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022) -
Update on Anticytokine Treatment for Asthma
por: Gallelli, Luca, et al.
Publicado: (2013) -
Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma
por: Pelaia, Girolamo, et al.
Publicado: (2015) -
Omalizumab, the first available antibody for biological treatment of
severe asthma: more than a decade of real-life effectiveness
por: Pelaia, Corrado, et al.
Publicado: (2018)